Back to search

Switzerland· 69481002

Tepkinly 48 mg/0,8 ml, Injektionslösung

A epcoritamab product containing epcoritamabum, registered in Switzerland by AbbVie AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FX27

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTepkinly 48 mg/0,8 ml, Injektionslösu…ATCL01FX27REGISTER NO.69481002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Epcoritamab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FX27 (epcoritamab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Epcoritamab · ATC L01FX27

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of epcoritamab costs, country by country.

Normalised to the WHO defined daily dose (1.7 mg), so markets compare like for like.

  • Switzerland: $281.38 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Epcoritamab · price per daily dose (1.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$281.38
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
epcoritamabum
Manufacturer
AbbVie AG
Country
Switzerland (CH)
ATC code
L01FX27
ATC class
Epcoritamab
Defined daily dose
1.7 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680694810029
    1 Stk
    CHF 6588.85

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Epcoritamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All epcoritamab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Tepkinly
  • Iceland · Tepkinly
  • Liechtenstein · Tepkinly
  • Norway · Tepkinly

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cd25c42c-6293-4934-bbc0-d840bd2b6e2a
GET /v1/drugs/cd25c42c-6293-4934-bbc0-d840bd2b6e2a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "epcoritamabum 48 mg",
  "valid_from": "2026-08-01",
  "limitations": "[{\"description\":\"Nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorheriger Konsultation des Vertrauensarztes.<br>\\nTEPKINLY wird vergütet als Monotherapie zur Behandlung von erwachsenen Patienten mit einem rezidivierenden oder refraktären diffusen grosszelligen B‐Zell-Lymphom (diffuse large B-cell lymphoma, DLBCL) nach zwei oder mehr systemischen Therapielinien, einschliesslich eines CD20-gerichteten Antikörpers,<br>\\n- welche für eine anti-CD19-gerichtete CAR-T-Zelltherapie nicht in Frage kommen oder diese bereits erhalten haben UND<br>\\n- bei denen keine ZNS-Beteiligung des Lymphoms vorliegt.<br>\\nDie Behandlung mit TEPKINLY wird vergütet, bis eine Krankheitsprogression oder inakzeptable Toxizität auftritt.<br>\\n<br>\\nFür TEPKINLY bestehen Preismodelle. Die Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin, für jede bezogene Packung TEPKINLY einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Indikationscode ist an den Krankenversicherer zu übermitteln: 21741.01<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21741.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\",\"validTo\":\"2027-04-30\"}]",
  "galenic_form": "Inj Lös 48 mg/0.8 ml Durchstf",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-12-01",
  "self_retention_pct": 10
}

See everything about epcoritamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.